The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.

Citation metadata

Date: Jan. 19, 2021
Publisher: American Medical Association
Document Type: Viewpoint essay
Length: 52 words

Document controls

Main content

Abstract :

Prioritizing all placebo-group participants in SARS-CoV-2 vaccine trials as first receivers could perpetuate health inequities and compromise the chance to learn from their participation. Prioritization can be limited to those who would be prioritized for vaccination anyway under National Academies of Science, Engineering and Medicine or Advisory Committee on Immunization Practices frameworks.

Source Citation

Source Citation   

Gale Document Number: GALE|A653148095